Lumos Pharma — NewLink Genetics — FY2018 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Feb 27, 2019
Slide 1: Fourth Quarter and Full Year 2018 Financial Results
Fourth Quarter and Full Year 2018 Financial Results NewLink Genetics Corporation Nasdaq: NLNK February 27, 2019
Slide 2: Agenda
•Lisa Miller, Director of Investor Relations Agenda • Charles J. Link, Jr, MD, Chairman, CEO & CSO •Eugene Kennedy, MD, Chief Medical Officer • Carl Langren, Chief Financial Officer 2
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,
Slide 4: NewLink Genetics Clinical Programs
NLG207 plus paclitaxel in recurrent ovarian cancer Recurrent . NLG207 is a nanoparticle formulation of topoisomerase 1 ovarian cancer inhibitor, camptothecin . Phase 2 results accepted for presentation at AACR in April 2019 NLG207 Front-line diffuse Indoximod plus radiotherapy for pediatric patients
Slide 5: Other Opportunities
Other Opportunities Ebola VSV-ZEBOV (V920) vaccine . Merck has announced they began rolling BLA submission process . NewLink holds substantial interest in potential Priority Review Voucher (PRV) Continue to pursue additional opportunities to expand our pipeline 5
Slide 6: NLG207 in Ovarian Cancer
NLG207 NLG207 (formerly CRLX101) Ovarian Cancer . Nanoparticle formulation of the Approximately topoisomerase 1 inhibitor camptothecin Roughly 70 percent . Originally acquired from Cerulean Pharma 22,530 of patients diagnosed with ovarian cancer in 2017 women will be diagnosed 3 1 . Phase 2 trial to
Slide 7: Indoximod and NLG802 Pipeline
Front-line Indoximod plus radiotherapy for pediatric patients with DIPG diffuse intrinsic . Early data show all patients demonstrated initial symptomatic improvement on pontine therapy with evidence of deep radiographic responses glioma (DIPG) . Phase 1b trial ongoing with updated data anticipated 2
Slide 8: Financial Position
Financial Position Q4 2018 End Cash and Equivalents $120.7 Million Average Quarterly Cash Use Projected ~$10 Million Cash Runway Projected Through 2021 Shares Outstanding as of December 31, 2018 37.25 Million 8
Slide 9: NewLink Genetics: Key Takeaways
NewLink Genetics: Key Takeaways Targeting Indications of Need Strong Cash Position Upcoming Presentations . Current clinical development Cash on hand at Q4 end April 2019: Phase 2 results for programs include: $120.7 million NLG207 in recurrent refractory ovarian, fallopian tube, or primary NL
Slide 10: ‘NewLink
‘NewLink